vs

Side-by-side financial comparison of ARTESIAN RESOURCES CORP (ARTNA) and REGENXBIO Inc. (RGNX). Click either name above to swap in a different company.

REGENXBIO Inc. is the larger business by last-quarter revenue ($30.3M vs $28.0M, roughly 1.1× ARTESIAN RESOURCES CORP). ARTESIAN RESOURCES CORP runs the higher net margin — 14.8% vs -221.3%, a 236.1% gap on every dollar of revenue. On growth, REGENXBIO Inc. posted the faster year-over-year revenue change (43.0% vs 4.3%). ARTESIAN RESOURCES CORP produced more free cash flow last quarter ($-7.9M vs $-52.8M). Over the past eight quarters, REGENXBIO Inc.'s revenue compounded faster (39.4% CAGR vs 6.8%).

Artesian Resources Corp is a US-headquartered regulated water utility and wastewater service provider, primarily serving residential, commercial, industrial and municipal customers across Delaware. It focuses on delivering safe, reliable drinking water supply and sustainable wastewater treatment solutions to local communities.

REGENXBIO Inc. is a clinical-stage biotechnology firm focused on gene therapy for rare severe genetic diseases. It licenses its proprietary AAV vector technology to global biopharma partners, and advances its own pipeline targeting ophthalmology, metabolic and neurodegenerative disorders.

ARTNA vs RGNX — Head-to-Head

Bigger by revenue
RGNX
RGNX
1.1× larger
RGNX
$30.3M
$28.0M
ARTNA
Growing faster (revenue YoY)
RGNX
RGNX
+38.7% gap
RGNX
43.0%
4.3%
ARTNA
Higher net margin
ARTNA
ARTNA
236.1% more per $
ARTNA
14.8%
-221.3%
RGNX
More free cash flow
ARTNA
ARTNA
$44.9M more FCF
ARTNA
$-7.9M
$-52.8M
RGNX
Faster 2-yr revenue CAGR
RGNX
RGNX
Annualised
RGNX
39.4%
6.8%
ARTNA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ARTNA
ARTNA
RGNX
RGNX
Revenue
$28.0M
$30.3M
Net Profit
$4.1M
$-67.1M
Gross Margin
Operating Margin
20.6%
-190.0%
Net Margin
14.8%
-221.3%
Revenue YoY
4.3%
43.0%
Net Profit YoY
7.5%
-31.2%
EPS (diluted)
$0.39
$-1.30

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARTNA
ARTNA
RGNX
RGNX
Q4 25
$28.0M
$30.3M
Q3 25
$30.5M
$29.7M
Q2 25
$28.5M
$21.4M
Q1 25
$25.9M
$89.0M
Q4 24
$26.9M
$21.2M
Q3 24
$29.1M
$24.2M
Q2 24
$27.4M
$22.3M
Q1 24
$24.5M
$15.6M
Net Profit
ARTNA
ARTNA
RGNX
RGNX
Q4 25
$4.1M
$-67.1M
Q3 25
$7.0M
$-61.9M
Q2 25
$6.3M
$-70.9M
Q1 25
$5.4M
$6.1M
Q4 24
$3.8M
$-51.2M
Q3 24
$6.8M
$-59.6M
Q2 24
$5.3M
$-53.0M
Q1 24
$4.4M
$-63.3M
Gross Margin
ARTNA
ARTNA
RGNX
RGNX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
70.2%
Q3 24
48.8%
Q2 24
52.5%
Q1 24
72.6%
Operating Margin
ARTNA
ARTNA
RGNX
RGNX
Q4 25
20.6%
-190.0%
Q3 25
28.3%
-176.3%
Q2 25
27.5%
-296.3%
Q1 25
21.4%
13.6%
Q4 24
21.0%
-242.1%
Q3 24
29.5%
-256.6%
Q2 24
26.3%
-251.3%
Q1 24
19.2%
-408.8%
Net Margin
ARTNA
ARTNA
RGNX
RGNX
Q4 25
14.8%
-221.3%
Q3 25
22.8%
-208.3%
Q2 25
22.0%
-331.8%
Q1 25
21.0%
6.8%
Q4 24
14.3%
-241.3%
Q3 24
23.4%
-246.3%
Q2 24
19.4%
-237.7%
Q1 24
18.0%
-405.4%
EPS (diluted)
ARTNA
ARTNA
RGNX
RGNX
Q4 25
$0.39
$-1.30
Q3 25
$0.68
$-1.20
Q2 25
$0.61
$-1.38
Q1 25
$0.53
$0.12
Q4 24
$0.37
$-0.99
Q3 24
$0.66
$-1.17
Q2 24
$0.52
$-1.05
Q1 24
$0.43
$-1.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARTNA
ARTNA
RGNX
RGNX
Cash + ST InvestmentsLiquidity on hand
$52.0K
$230.1M
Total DebtLower is stronger
$176.4M
Stockholders' EquityBook value
$249.9M
$102.7M
Total Assets
$851.2M
$453.0M
Debt / EquityLower = less leverage
0.71×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARTNA
ARTNA
RGNX
RGNX
Q4 25
$52.0K
$230.1M
Q3 25
$705.0K
$274.2M
Q2 25
$349.0K
$323.3M
Q1 25
$3.7M
$267.9M
Q4 24
$1.1M
$234.7M
Q3 24
$10.7M
$255.5M
Q2 24
$6.3M
$290.4M
Q1 24
$9.5M
$338.7M
Total Debt
ARTNA
ARTNA
RGNX
RGNX
Q4 25
$176.4M
Q3 25
Q2 25
Q1 25
Q4 24
$178.7M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ARTNA
ARTNA
RGNX
RGNX
Q4 25
$249.9M
$102.7M
Q3 25
$248.8M
$161.5M
Q2 25
$244.9M
$213.7M
Q1 25
$241.7M
$274.2M
Q4 24
$239.2M
$259.7M
Q3 24
$238.3M
$301.4M
Q2 24
$234.4M
$348.3M
Q1 24
$232.0M
$390.7M
Total Assets
ARTNA
ARTNA
RGNX
RGNX
Q4 25
$851.2M
$453.0M
Q3 25
$833.9M
$525.2M
Q2 25
$819.3M
$581.0M
Q1 25
$808.9M
$490.9M
Q4 24
$798.6M
$466.0M
Q3 24
$796.0M
$519.1M
Q2 24
$783.1M
$569.4M
Q1 24
$798.6M
$629.2M
Debt / Equity
ARTNA
ARTNA
RGNX
RGNX
Q4 25
0.71×
Q3 25
Q2 25
Q1 25
Q4 24
0.75×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARTNA
ARTNA
RGNX
RGNX
Operating Cash FlowLast quarter
$10.5M
$-52.3M
Free Cash FlowOCF − Capex
$-7.9M
$-52.8M
FCF MarginFCF / Revenue
-28.1%
-174.0%
Capex IntensityCapex / Revenue
65.4%
1.7%
Cash ConversionOCF / Net Profit
2.53×
TTM Free Cash FlowTrailing 4 quarters
$-18.5M
$-126.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARTNA
ARTNA
RGNX
RGNX
Q4 25
$10.5M
$-52.3M
Q3 25
$11.0M
$-56.0M
Q2 25
$7.9M
$-49.3M
Q1 25
$11.0M
$33.6M
Q4 24
$6.7M
$-31.6M
Q3 24
$10.7M
$-40.5M
Q2 24
$6.9M
$-45.5M
Q1 24
$12.6M
$-55.5M
Free Cash Flow
ARTNA
ARTNA
RGNX
RGNX
Q4 25
$-7.9M
$-52.8M
Q3 25
$-3.3M
$-56.5M
Q2 25
$-7.9M
$-49.7M
Q1 25
$560.0K
$32.6M
Q4 24
$-8.3M
$-32.7M
Q3 24
$-1.9M
$-40.9M
Q2 24
$-2.6M
$-46.0M
Q1 24
$3.7M
$-56.0M
FCF Margin
ARTNA
ARTNA
RGNX
RGNX
Q4 25
-28.1%
-174.0%
Q3 25
-10.7%
-189.9%
Q2 25
-27.8%
-232.8%
Q1 25
2.2%
36.6%
Q4 24
-30.9%
-154.2%
Q3 24
-6.5%
-168.9%
Q2 24
-9.4%
-206.2%
Q1 24
15.0%
-358.5%
Capex Intensity
ARTNA
ARTNA
RGNX
RGNX
Q4 25
65.4%
1.7%
Q3 25
46.7%
1.7%
Q2 25
55.6%
1.8%
Q1 25
40.2%
1.2%
Q4 24
55.9%
5.1%
Q3 24
43.1%
1.3%
Q2 24
34.5%
2.1%
Q1 24
36.4%
3.6%
Cash Conversion
ARTNA
ARTNA
RGNX
RGNX
Q4 25
2.53×
Q3 25
1.58×
Q2 25
1.26×
Q1 25
2.02×
5.53×
Q4 24
1.74×
Q3 24
1.56×
Q2 24
1.29×
Q1 24
2.86×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ARTNA
ARTNA

Water Sales$22.3M80%
Other Utility Operating Revenue$3.8M14%
Non Utility Operating Revenue$1.9M7%

RGNX
RGNX

Novartis Gene Therapies$24.2M80%
Nippon Shinyaku Collaboration And License Agreement$4.3M14%
Nippon Shinyaku Services$1.4M5%

Related Comparisons